Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100

Cancer

Volumn 106, Issue 4, 2006, Pages 890-899

  Spaner, David E ^a,b,c,g   Astsaturov, Igor ^a   Vogel, Thorsten ^d   Petrella, Teresa ^b,c   Elias, Ileana ^d   Burdett Radoux, Susan ^e   Verma, Shailendra ^f   Iscoe, Neill ^b,c   Hamilton, Paul ^a   Berinstein, Neil L ^b,c,d  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Cancer Vaccine Program   (Canada)

^e ROYAL VICTORIA HOSPITAL   (Canada)

^f OTTAWA REGIONAL CANCER CENTRE   (Canada)

^g Sunnybrook Health Sciences Centre   (Canada)

Author keywords

Human; Tumor immunity; Vaccination; Viral

Indexed keywords

GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 100 PEPTIDE; MELANOMA ANTIGEN; PEPTIDE DERIVATIVE; TETANUS TOXOID; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADULT; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CANARYPOX VIRUS; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HELPER CELL; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INTRANODAL DRUG ADMINISTRATION; LYMPH NODE; MALE; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TOXICITY; TUMOR IMMUNITY; VACCINATION;

ADULT; AGED; CANARYPOX VIRUS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; HLA-A ANTIGENS; HUMANS; INJECTIONS, SUBCUTANEOUS; LYMPHATIC METASTASIS; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; SKIN NEOPLASMS; TETANUS TOXOID;

EID: 32544451003     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21669     Document Type: Article

References (30)

1. Berzofsky JA, Terabe M, Oh S, et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest. 2004;113:1515-1525.
2. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother. 2001;50:3-15.
3. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol. 1995;154:3961-3968.
4. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
5. Weber J, Sondak VK, Scotland R, et al. GM-CSF added to a multipeptide vaccine for resected stage II melanoma. Cancer. 2003;97:186-200.
6. Kwak H, Horig H, Kaufman HL. Poxviruses as vectors for cancer immunotherapy. Curr Opin Drug Discov Devel. 2003;6:161-168.
7. St George JA. Gene therapy progress and prospects: adenoviral vectors. Gene Ther. 2003;10:1135-1141.
8. Perkus ME, Tartaglia J, Paoletti E. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J Leukoc Biol. 1995;58:1-13.
9. de Bruyn G, Rossini AJ, Chiu YL, et al. Safety profile of recombinant canarypox HIV vaccines. Vaccine. 2004;22:704-713.
10. Fries LF, Tartaglia J, Taylor J, et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine. 1996;14:428-434.
11. van der Burg SH, Menon AG, Redeker A, et al. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin Cancer Res. 2002;8:1019-1027.
12. Pialoux G, Excler JL, Riviere Y, et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing gp160 followed by recombinant gp160. AIDS Res Hum Retroviruses. 1995;11:373-381.
13. Kundig TM, Shahinian A, Kawai K, et al. Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity. 1996;5:41-52.
14. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med. 1999;189:753-756.
15. Elliott SL, Pye S, Le T, et al. Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems. Vaccine. 1999;17:2009-2019.
16. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A* 0201-binding residues. J Immunol. 1996;157:2539-2548.
17. Astsaturov I, Petrella T, Bagriacik EU, et al. Amplification of virus-induced antimelanoma T-cell reactivity by high-dose IFNα2b. Clin Cancer Res. 2003;9:4347-4355.
18. Slingluff CL, Petroni GR, Yamshchikov GV, et al. Immunologi and clinical outcomes of vaccination with a multi-epitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol. 2004;22:4474-4485.
19. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321-327.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
21. Rosenberg SA, White DE. Vitiligo in patients with melanoma. J Immunother Emphasis Tumor Immunol. 1996;19:81-84.
22. Zinkernagel RM, LaMarre A, Ciurea A, et al. Neutralizing antiviral antibody responses. Adv Immunol. 2001;79:1-53.
23. Chianese-Bullock KA, Pressley J, Garbee C, et al. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with GM-CSF and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol. 2005;174:3080-3086.
24. + T-cell function in melanoma patients. J Clin Oncol. 2003;21:3826-3835.
25. Williams TW, Yanagimoto JM, Mazumder A, Wiseman CL. IL-2 increases the antibody response in patients receiving autologous intralymphatic tumor cell vaccine immunotherapy. Mol Biother. 1992;4:66-69.
26. Tagawa ST, Lee P, Snively J, et al. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with stage IV melanoma. Cancer. 2003;98:144-154.
27. Selin LK, Vergilis K, Welsh RM, Nahill SR. Reduction of otherwise remarkably stable virus-specific cytotoxic T lymphocyte memory by heterologous viral infections. J Exp Med. 1996;183:2489-2499.
28. + stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin Cancer Res. 2004;10:668-680.
29. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
30. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.